Hydrochloric Acid

Hydrochloric Acid

SCHEMBL784637

Cl.O=S(=O)(O)c1ccccc1Cl

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 known ✓ P28845 4/20 0.46
GAA known ✓ P10253 1/20 0.43
FLT1 known ✓ P17948 1/20 0.41
FLT4 known ✓ P35916 1/20 0.41
KDR known ✓ P35968 1/20 0.41
TTR known ✓ P02766 1/20 0.41
TSHR P16473 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MYC P01106 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NFE2L2 Q16236 4/20 0.42
POLB P06746 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
LMNA P02545 1/20 0.41
AKR1B1 P15121 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30454753 0.98 HSD11B1 (0.47) HSD11B1TSHRALDH1A1GAAHSD17B10
SCHEMBL50612 0.98 HSD11B1 (0.47) HSD11B1TSHRALDH1A1GAAHSD17B10
SCHEMBL6908684 0.95 HSD11B1 (0.46) HSD11B1TSHRALDH1A1GAAHSD17B10
SCHEMBL6917692 0.95 HSD11B1 (0.46) HSD11B1TSHRALDH1A1GAAHSD17B10
Ammonia Solution, Strong SCHEMBL11794102 0.95 HSD11B1 (0.46) HSD11B1TSHRALDH1A1GAAHSD17B10
Water SCHEMBL9360422 0.95 HSD11B1 (0.46) HSD11B1TSHRALDH1A1GAAHSD17B10
SCHEMBL3709429 0.95 HSD11B1 (0.46) HSD11B1TSHRALDH1A1GAAHSD17B10
SCHEMBL6908686 0.95 HSD11B1 (0.46) HSD11B1TSHRALDH1A1GAAHSD17B10
SCHEMBL2880274 0.95 HSD11B1 (0.50) HSD11B1TSHRALDH1A1GAAHSD17B10
SCHEMBL6918638 0.95 HSD11B1 (0.46) HSD11B1TSHRALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106831814-B A kind of thieno [3,2-d] miazines HIV-1 reverse transcriptase inhibitor and its preparation method and application 山东大学 2018-11-23 CN claimed
CN-106831814-A A kind of thieno [3,2 d] RTIs of miazines HIV 1 and its preparation method and application 山东大学 2017-06-13 CN claimed
CN-105837528-A Preparation method of 2- (methylsulfonyl) -10H-phenothiazine 大连理工大学 2016-08-10 CN claimed
US-4880576-A HALOGENATION OF ACIDS, FORMAMIDE CATALYSTS BAYER AKTIENGESELLSCHAFT (DE) 1989-11-14 US claimed
JP-1090260-A None JP disclosed
EP-4055010-A1 SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS Bayer Aktiengesellschaft (DE) 2022-09-14 EP disclosed
US-11015061-B2 Phthalocyanine-based compound and uses of same YAMAMOTO CHEMICALS, INC. (JP) 2021-05-25 US disclosed
WO-2020071470-A1 PHTHALOCYANINE COMPOUND AND USE THEREOF 山本化成株式会社 2020-04-09 WO disclosed
US-20200032066-A1 PHTHALOCYANINE-BASED COMPOUND AND USES OF SAME YAMAMOTO CHEMICALS, INC. (JP) 2020-01-30 US disclosed
EP-3534709-A1 SUBSTITUTED SULFONYL AMIDES FOR CONTROLLING ANIMAL PESTS Bayer Aktiengesellschaft (DE) 2019-09-11 EP disclosed
CN-106232584-B As 6 inhibitor of histone deacetylase new compound and include its pharmaceutical composition 株式会社钟根堂 2019-06-28 CN disclosed
CN-105873577-B Cycloalkenylamides as bromodomain inhibitors 西奈山伊坎医学院 2019-06-18 CN disclosed
US-20110021488-A1 New Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 US disclosed
US-7858618-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-28 US disclosed
US-20090137545-A1 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 US disclosed
CN-1767823-A Asthma and allergic inflammation modulators AMGEN INC (US) 2006-05-03 CN disclosed
CN-1064063-C Process for producing dioxazine compounds, colored materials therewith and plate crystals thereof NIPPON KAYAKU KK (JP) 2001-04-04 CN disclosed
US-4871876-A HEATING CHLOROBENZENE WITH CHLOROSULFONIC ACID, SULFUR TRIOXIDE, WHIONYL CHLORIDE AND PHOSGENE DRESSER INDUSTRIES, INC. (US) 1989-10-03 US disclosed
US-4388246-A THERMAL SPLITTING OF CARBAMATES BAYER AKTIENGESELLSCHAFT (DE) 1983-06-14 US disclosed
US-4060549-A Process for preparing sulfonic acid fluorides BAYER AKTIENGESELLSCHAFT (DT) 1977-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137545-A1 Compounds ADORA2B, ABCB11, CYP11B1 HSD11B1 114/4885GAA 1182/4885FLT1 2099/4885
US-20110021488-A1 New Compounds ABCG2, ADORA2B, ADORA3 HSD11B1 210/4885GAA 1275/4885FLT1 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.